Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > October 4, 2022
Daily News
October 4, 2022
- Sumitomo Rolls Out Hand Rehabilitation System in Japan as 1st Frontier Business Product
October 4, 2022
- Idorsia’s Insomnia Med Meets PIII Goal in Japan, Filing Planned for H1 2023
October 4, 2022
- Japan Convenes Diet Session; Bill Submission Planned to Amend Infectious Disease Act, Medical Care Act
October 4, 2022
- Shionogi to End Sale of Aimix, Sumitomo to Continue
October 4, 2022
- Govt Plans to Designate Key Resources Before End of Year: Minister
October 4, 2022
- Taiho Gets US Nod for Bile Duct Cancer Drug Futibatinib
October 4, 2022
- Sun Pharma Taps Haruko Yamabe as Japan Chief
October 4, 2022
- Novartis Homes in on 5 Therapy Areas and 4 Markets, Eyes Top 3 Multinational Rank in Japan: CEO
October 4, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…